Delayed Anti-CD3 Therapy Results in Depletion of Alloreactive T Cells and the Dominance of Foxp3(+)CD4(+) Graft Infiltrating Cells

The engineered Fc-nonbinding (crystallizable fragment-nonbinding) CD3 antibody has lower mitogenicity and a precise therapeutic window for disease remission in patients with type 1 diabetes. Before anti-CD3 can be considered for use in transplantation, the most effective timing of treatment relative...

Descripción completa

Detalles Bibliográficos
Autores principales: Goto, R, You, S, Zaitsu, M, Chatenoud, L, Wood, KJ
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2013
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3790953/
https://www.ncbi.nlm.nih.gov/pubmed/23750800
http://dx.doi.org/10.1111/ajt.12272

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3790953/
https://www.ncbi.nlm.nih.gov/pubmed/23750800
http://dx.doi.org/10.1111/ajt.12272

Ejemplares similares